Results 41 to 50 of about 6,459 (257)

Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J‐mono trial

Journal of Diabetes Investigation
Aims/Introduction In the SURPASS J‐mono trial, tirzepatide demonstrated significant improvements in bodyweight and several metabolic parameters in Japanese participants with type 2 diabetes.
Hanaka Mimura, Tomonori Oura, Rina Chin, Masakazu Takeuchi, Kazuya Fujihara, Hirohito Sone   +5 more
doaj   +1 more source

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis

Frontiers in Pharmacology
Background: Tirzepatide—a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist—is used to treat type 2 diabetes.
Emiko Otsuka, Emiko Otsuka, Mineaki Kitamura, Mineaki Kitamura, Satoshi Funakoshi, Hiroshi Mukae, Tomoya Nishino   +6 more
doaj   +1 more source

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Chemistry – A European Journal, EarlyView.
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova, Jan L. Venne, Sona Krajcovicova, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah Bolt, Andie Collinson, Jason Day, Jefferson Revell, David R. Spring   +11 more
wiley   +1 more source

Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.

, 2023
AIM: To perform a meta-analysis to quantify the effect of tirzepatide on blood pressure and lipids. METHODS: PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evaluating
Tuttle, Katherine, Gaipov, Abduzhappar, Copur, Sidar, Yildiz, Abdullah Burak, van Raalte, Daniel H, Kanbay, Mehmet, Siriopol, Dimitrie   +6 more
core   +1 more source

Assessing the therapeutic potential of Tirzepatide in modulating inflammatory responses and mitigating acute pancreatitis

Animal Models and Experimental Medicine
Background Acute pancreatitis (AP) is a severe inflammation of the pancreas, marked by elevated enzyme levels, cellular inflammation, and necrosis. Recent studies emphasize the critical role of inflammation in AP progression.
Razan Alawaji, Mohamed S. Abdel‐Bakky, Hussein M. Ali, Miad A. Aljuhani, Abdulaziz Arif A. Alshammari, Hashim K. Kamal, Maamoun M. K. Khoja, Kholoud Alsehemi, Mennatallah A. Korani, Eman S. Said   +9 more
doaj   +1 more source

Tirzepatide-related acute liver injury

European Journal of Case Reports in Internal Medicine
Tirzepatide, a modified protein containing 39 amino acids, acts as a dual agonist at the gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, showing great promise in weight-loss treatment.
Irrum Abdullah, Husam El-Ghousain, Meshaan Alenezi   +2 more
doaj   +1 more source

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Cardiovascular Diabetology, 2022
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin ...
Michael A. Nauck, David A. D‘Alessio
doaj   +1 more source

Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

JEADV Clinical Practice, EarlyView.
ABSTRACT Background There is a growing body of literature suggesting that GLP‐1 receptor agonists (GLP‐1RAs) may be associated with hair loss; however, primary literature is sparse. Additionally, it is not well‐established which types of hair loss may be associated with GLP‐1RA use. Objectives This study aims to assess associations between GLP‐1RAs and
Lauren M. Ching, Christopher A. Guirguis, Joe K. Tung   +2 more
wiley   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity

, 2023
Tirzepatide is a combined glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. This review will summarize the pharmacological aspects of tirzepatide with a focus on the clinical efficacy and safety ...
A. Bronden, M.B. Christensen, Christensen, Mikkel Bring, K. Karstoft, T.L. Jensen, D.P. Sonne, Jensen, Thomas Leth, Karstoft, Kristian, Brønden, Andreas, Sonne, David Peick   +9 more
core   +1 more source